Attention Deficit Disorder with Hyperactivity
A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)
Drugs by status
Approved for this indication (15)
Phase 4 trials (18)
Phase 3 trials (26)
- centanafadine
- hypericum perforatum
- magnesium oxide
- edivoxetine
- vitamin c
- omega-6 fatty acids
- pine bark extract
- tocotrienol
- zolpidem
- dasotraline
- modafinil
- pyridoxine
- fasoracetam
- eszopiclone
- methylfolate
- omega-3 fatty acids
- fish oil
- solriamfetol
- onabotulinumtoxinA
- phosphatidylserine
- ubiquinone
- zinc
- spn-810
- wheat
- wumeiwan jiawei fang
- nrct-101
Phase 2 trials (45)
- pozanicline
- sofinicline
- brexpiprazole
- ar08
- azd-3480
- buspirone
- citalopram
- duloxetine
- droxidopa
- sertraline
- glyti-m
- amantadine
- bioactive factors, produced by m2 macrophage
- carbidopa
- theanine
- levocarnitine
- lobeline
- mazindol
- org-26576
- molindone
- gsk372475
- c-11 altropane
- pf-03654746
- lactose
- reboxetine
- cannabis
- bradanicline
- tipepidine hibenzate
- tolcapone
- v81444
- +15 more
Phase 1 trials (13)
Organizations
Organization Involved with Phase 4 Indications (113)
- Arbor Pharmaceuticals
- McNeil
- Shire
- Bristol-Myers Squibb
- Pfizer
- Shionogi
- Purdue Pharmaceuticals
- BRC Operations Pty. Ltd.
- Laboratorios Ordesa
- Lallemand SAS
- Noven Therapeutics
- Rhodes Pharmaceuticals, L.P.
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institute on Drug Abuse (NIDA)
- Douglas Sears
- UMC Utrecht
- Region Syddanmark
- Lori A. Schweickert, MD
- University of Pennsylvania
- Acadia University
- University of Arizona
- University of Pittsburgh
- Brown University
- Case Western Reserve University
- Children's Specialized Hospital
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Harvard University
- Duke University
- +83 more
Organization Involved with Phase 3 Indications (56)
- Spectrum Pharmaceuticals
- Cephalon
- Pamlab
- Sanofi
- Alza
- Alcobra Ltd.
- Aevi Genomic Medicine
- DSM
- Engelhard Arzneimittel GmbH & Co.KG
- GlaxoSmithKline
- Ironshore Pharmaceuticals and Development, Inc
- Medice Arzneimittel Pütter GmbH & Co KG
- Neos Therapeutics, Inc
- Orient Pharma Co., Ltd.
- Sunovion
- Tris Pharma, Inc.
- Vifor Inc.
- Yuyu Pharma, Inc.
- Durect
- Otsuka
- German Research Foundation
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- ZonMw: The Netherlands Organisation for Health Research and Development
- National Institute of Neurological Disorders and Stroke (NINDS)
- Maastricht University
- Allameh Tabatabai University
- Inje University
- Julius-Maximilians University
- The Canadian College of Naturopathic Medicine
- University of Oklahoma
- +26 more
Organization Involved with Phase 2 Indications (45)
- AbbVie
- Chelsea Therapeutics
- Ceptaris
- Targacept
- Theravance
- Vernalis
- AstraZeneca
- Merck
- CoMentis
- BioLite, Inc.
- Clinical Study Centers, LLC
- Mensia Technologies SA
- NeuroDerm Ltd.
- NeuroSearch A/S
- Neurovance, Inc.
- NLS Pharma Inc.
- RespireRx
- National Center for Complementary and Integrative Health (NCCIH)
- Bastyr University
- Chiba University
- Indiana University
- Johns Hopkins University
- Medical University of Warsaw
- Russian Academy of Medical Sciences
- University of Kentucky
- University of Santiago de Compostela
- University of South Carolina
- University of British Columbia
- Medical University of South Carolina
- University of Freiburg
- +15 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (31)
- Unilever
- BioLineRx, Ltd.
- Korea Research Foundation
- National Institute of Nursing Research (NINR)
- University of London
- Cox Health Systems
- Kyung Hee University
- Norwegian University of Science and Technology
- Tel Hai College
- Tufts University
- University of Michigan
- Yale University
- University of Virginia
- Taipei Medical University
- University of Ulm
- Food and Drug Administration
- pediatric neurology of the ozarks
- University of Massachusetts
- Ben Gurion University
- University of Colorado
- South London and Maudsley NHS Foundation Trust
- American Academy of Child Adolescent Psychiatry.
- Samsung
- Weizmann Institute of Science
- Sungkyunkwan University
- The American Professional Society of ADHD and Related Disorders (APSARD)
- Israel Association of Pediatricians
- China Medical University
- Government of Singapore
- Xijing Hospital
- +1 more